Tvardi Therapeutics (TVRD) Current Deferred Revenue (2013 - 2020)
Tvardi Therapeutics (TVRD) posted Current Deferred Revenue of $511000.0 for Q3 2020, down 94.77% sequentially from $9.8 million in Q2 2020, and down 98.09% YoY from $26.8 million in Q4 2019.
Tvardi Therapeutics (TVRD) Current Deferred Revenue (2013 - 2020) Analysis & Trends
Tvardi Therapeutics has reported Current Deferred Revenue for 6 years, with the latest figure at $511000.0 in Q3 2020.
- Quarterly Current Deferred Revenue fell 98.09% year-over-year to $511000.0 in Q3 2020, while the trailing twelve-month figure through Sep 2020 was $511000.0 (down 98.09% YoY) and the FY2019 annual result came in at $22.3 million, down 17.01% from the prior year.
- Current Deferred Revenue fell to $511000.0 in Q3 2020 per TVRD's latest filing, from $9.8 million in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $29.2 million in Q3 2018 and troughed at $511000.0 in Q3 2020.
- A 3-year average of $20.7 million and a median of $24.4 million in 2018 frame the typical range for Current Deferred Revenue.
- The sharpest annual moves came in 2019 and 2020: Current Deferred Revenue gained 18.87% in 2019, then tumbled 98.09% in 2020.
- Over 3 years, Current Deferred Revenue stood at $26.8 million in 2018, then decreased by 17.01% to $22.3 million in 2019, then tumbled by 97.7% to $511000.0 in 2020.
- According to Business Quant data, Current Deferred Revenue over the past three periods registered $511000.0, $9.8 million, and $14.2 million for Q3 2020, Q2 2020, and Q1 2020 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2020 | 511,000.00 |
| Jun 30, 2020 | 9.77 Mn |
| Mar 31, 2020 | 14.24 Mn |
| Dec 31, 2019 | 22.26 Mn |
| Sep 30, 2019 | 26.77 Mn |
| Jun 30, 2019 | 26.47 Mn |
| Mar 31, 2019 | 28.19 Mn |
| Dec 31, 2018 | 26.83 Mn |
| Sep 30, 2018 | 29.24 Mn |
| Jun 30, 2018 | 22.27 Mn |
| Jun 30, 2015 | 89,000.00 |
| Mar 31, 2015 | 963,000.00 |
| Dec 31, 2014 | 1.45 Mn |
| Sep 30, 2014 | 1.94 Mn |
| Jun 30, 2014 | 90,000.00 |
| Mar 31, 2014 | 3.42 Mn |
| Dec 31, 2013 | 3.48 Mn |